Navigation Links
ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes
Date:7/10/2013

at regulate blood glucose in a manner similar or identical to a normal pancreas. 

Kevin D'Amour, Ph.D., ViaCyte's Chief Scientific Officer, recently provided an update on VC-01 during a presentation at the 73rd Scientific Sessions of the American Diabetes Association entitled Development of an Encapsulated Stem Cell-Based Therapy for Diabetes. The presentation highlighted the tremendous progress ViaCyte has made in the preclinical development of VC-01.  ViaCyte is currently planning to file its Investigational New Drug (IND) application with the Federal Drug Administration (FDA) to initiate clinical trials in patients with type 1 diabetes early next year.  If VC-01 performs in humans as it has in preclinical studies, it could significantly alleviate or eliminate the challenges and complications for Type 1 diabetics who manage their disease through careful control of diet, monitoring of blood glucose levels and injection of insulin.

The SPA from CIRM provides ViaCyte with $10.1 million to support the clinical study planned for next year and complements previous funding from CIRM.  This award reflects CIRM's commitment to follow promising science through the progressive stages of product development.  The Company has also received and continues to receive both scientific and financial support for the development of VC-01 from JDRF.

Paul Laikind, Ph.D., ViaCyte's president and chief executive officer, said, "We are very gratified by the continued support of our investors and CIRM as we prepare to evaluate the safety and efficacy of VC-01.  This promising product candidate has the potential to vastly improve the lives of millions of patients who currently require insulin injections to survive.  Moreover, success of VC-01 will validate ViaCyte's proprietary, stem cell-derived cell therapy platform that has multiple applications, as well as demonstrate the full utility
'/>"/>

SOURCE ViaCyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Acutus Medical, Inc. Raises $21 Million Toward its B-Series Financing
2. TVA Medical Raises $9.5 Million to Advance Minimally Invasive Therapy for End-Stage Renal Disease
3. Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
4. AMRI Announces First Quarter 2013 Results and Raises EPS Guidance for the Year
5. NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
6. Minimally Invasive Devices Raises $9 Million in Series B Financing to Commercialize Laparoscopic Visualization Product
7. PCMA: New Report Shows Drugstore Lobby Agenda Raises Rx Costs for Small Businesses, Government Programs
8. Promotion Raises Awareness of Scar Treatment
9. MacuLogix Raises $3.6 Million in Series A Round
10. Leader In At-Home Laboratory Testing Praises Federal Panels Recommendations For Widespread HIV Testing
11. Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Cerevast Therapeutics ... today the outcome of the first interim analysis ... the Company,s proprietary Clotbust ER TM ... ischemic stroke. The independent Data Safety Monitoring Board ... planned. "Clearing the pre-specified futility threshold ...
(Date:9/23/2014)... Norway , September 23, 2014 ... an oncology biopharmaceutical company, today announces it has ... Seeding Drug Discovery Award from the UK,s Wellcome ... BGB002, its proprietary, novel cancer target. ... to identify and fund especially promising, innovative new ...
(Date:9/23/2014)... , Sept. 23, 2014 Enable ... that may soon make it easy and nearly painless ... comfort of their homes, has been named winner of ... innovative companies in the biotech sector.    Enable ... and received the greatest number of votes in the ...
Breaking Medicine Technology:Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 2Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 3BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2
(Date:9/23/2014)... as bridges that allow electrical signals to pass ... Rice University and Texas Children,s Hospital. , A ... engineer and chemist Matteo Pasquali created the patches ... are made of a sponge-like bioscaffold that contains ... , The nanotubes overcome a limitation of current ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 eCaring, ... it has entered into a contract to provide its ... to Elderplan, Inc., one of New York City’s largest ... will deploy the eCaring system to help enhance the ... , “For nearly 30 years, Elderplan has been at ...
(Date:9/23/2014)... September 23, 2014New technology and better screening strategies can ... substantial financial and psychological burden on women. The many ... benefits and costs of screening, and the need for ... series of articles in a supplement to Journal ... Ann Liebert, Inc., publishers. The supplement is available free ...
(Date:9/23/2014)... of four dogs will develop cancer in their lifetime ... cases. , A team of researchers from the University ... develop a new user-friendly electronic system for diagnosing lymphoma ... monitoring. , Marketed as cLBT (canine lymphoma blood ... to track the remission monitoring status of a dog ...
(Date:9/23/2014)... On September 23, 2014, My Positive Perspective ... episode. Simmons is the founder of Traveler of Charleston magazine ... like to know. At the start of the interview, Deierlein ... this magazine?” Simmons replied by saying, “I had worked for ... I quit that and decided to start my own magazine ...
Breaking Medicine News(10 mins):Health News:Nanotubes help healing hearts keep the beat 2Health News:Nanotubes help healing hearts keep the beat 3Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2Health News:Opportunities to reduce patient burden associated with breast cancer screening 2Health News:New hope for beloved family pets 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... July 29 Market trends indicate that consumers want ... well-being and natural beauty. At the X-Ceuticals Conference ... technical professionals will hear expert presentations and view demonstrations ... that will generate creative new ideas and product opportunities ...
... , , , , ... HTWR , ASX: HIN) today announced that its Annual Meeting ... 7:00 pm US Eastern today, July 29 (9:00 am Sydney time on ... be webcast and may be viewed at the Company,s website ( ...
... , SANTA ROSA, Calif., July 29 Rick Weekley ... by champion racehorse Rachel Alexandra prior to her historic victory in the ... 1924. The winning bid--$2,859.99--will be donated by the horse,s owners, Jess Jackson ... , Today, the second item in the five-item series will ...
... ... a two-day workshop on Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications from ... ... (DIA) will host a two-day workshop on Cardiovascular Safety and Development of Type ...
... analysing MRI changes occuring in the brains of children ... at Heidelberg University Hospital have succeeded for the first ... well as elucidating its temporal evolution. The ... the disease, the products of metabolism cause not only ...
... of a Tyrannosaurus rex (T. rex) that roamed Earth ... and bone, tendons, or cartilage. The findings, scheduled for publication in ... Research , is the latest addition to an ongoing controversy over ... the study, Marshall Bern, Brett S. Phinney and David Goldberg point ...
Cached Medicine News:Health News:HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals 2Health News:HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals 3Health News:Ohio Man Top Bidder for Preakness Winner's Halter, First of Five Items in Horse's Season-Long Auction Series 2Health News:Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development 2Health News:Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development 3Health News:Therapy should extend beyond childhood 2Health News:Therapy should extend beyond childhood 3
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Representing the next step in the evolution of point-of-care testing, the i-STAT 1 Analyzer uses one platform to perform glucose strip testing along with all i-STAT test cartridges....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
... Extremely bright xenon illumination ... or other instruments. Port ... fiber optic cables. Worldwide ... Convenient lamp change drawer ...
Medicine Products: